Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Koustubh Ranade (Potomac, United States of America), Koustubh Ranade, Michael Kuziora, Tuyet-Hang Pham, Gautam Damera, Philip Z. Brohawn, Fernanda Pilataxi, Katie Streicher, Scott Martinez, Inna Vainshtein, Meina Liang, Dewei She, Edward Piper, Chrisopher E. Brightling, Richard Martin. Dipeptidyl peptidase-4 (DPP-4) may predict response to tralokinumab in patients with asthma. Eur Respir J 2016; 48: Suppl. 60, 1796

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Lack of association between circulating dipeptidyl peptidase-4 and type 2 biomarkers in asthma; data from U-BIOPRED and BIOAIR cohorts Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology Year: 2016 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Bronchial asthma (BA) pharmacogenetic profile and therapeutic resistance in slavic population Source: Annual Congress 2013 –Is it really asthma? Year: 2013 ADEPT, airway disease endotyping for personalized treatment: Interim analysis of asthma patients Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Study of therapeutics effects of montelukast in asthmatic children Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Dipeptidyl peptidase I (DPPI) cleaves surfactant protein D (SP-D): A mechanism for immune compromise in the lung Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Long-acting anti-muscarinic agents (LAMA) frequency of use and clinical features of patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of obesity and metabolic syndrome in patients with bronchial asthma Source: International Congress 2015 – Clinical assessment in asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Safety and tolerability of acute dosing of beta-blockers in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Safety of tiotropium in renally impaired patients Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Inflammation in COPD patients before and after roflumilast treatment Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016